Manuel Philip

snakemake-workflows/rna-seq-kallisto-sleuth: v4.1.0

Johannes Köster, David Laehnemann, F. Wiegand, Adrian Prinz et autres

4.1.0 (2026-08-17) Features lr-kallisto (#170) (e5db265) Bug Fixes update biomart to 2.66 and GOATOOLS to 1.6.4 (#175) (31cf0d9)

de, us (code pays fourni par la source)

Supplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

ConstHLA-II melanoma cells lack endogenous interferon expression

Supplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

HLA-II expression in longitudinal melanoma samples

Supplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61

Supplementary Figure S4 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

CD4 T-cell sensitivity of constHLA-II melanoma cells

Supplementary Figure S7 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients

Supplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells

Supplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells

RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma

Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Manuel Philip et autres

BACKGROUND: Cancer immunotherapy has transformed metastatic cancer treatment, yet challenges persist regarding therapeutic efficacy. RECQL4, a RecQ-like helicase, plays a central role in DNA replication and repair as part of the DNA damage response, a pathway implicated in enhancing efficacy of immune …

de, dk (code pays fourni par la source)

Supplementary Figure S6 from HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells

Supplementary Figure S3 from HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

ConstHLA-II melanoma cells lack endogenous interferon expression

Supplementary Figure S2 from HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba et autres

Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61